+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Eczema Therapeutics Market - Global Forecast 2026-2032- Product Image
Eczema Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Eczema Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674454
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Eczema Therapeutics Market is projected to reach USD 8.81 Billion in 2026. It is expected to continue growing at a CAGR of 7.01%, reaching USD 13.26 Billion by 2032.

Eczema therapeutics are shifting from broad symptom control to precision immunology, especially in atopic dermatitis, the most common inflammatory eczema subtype. Epidemiology reviews consistently report that eczema affects up to one in five children and approximately one in ten adults in many populations, creating sustained clinical demand for topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics, JAK inhibitors, emollients, and infection-management strategies.

Market momentum is supported by rising diagnosis, broader specialist access, patient demand for rapid itch control, and validated measures such as EASI, SCORAD, IGA, POEM, and DLQI. Competitive differentiation is increasingly centered on durable skin clearance, faster pruritus reduction, steroid-sparing control, pediatric expansion, manageable monitoring requirements, and clearly defined safety profiles for chronic relapsing disease.

Transformative Shifts in the Eczema Treatment Landscape

The eczema therapeutics landscape is being transformed by targeted immune modulation. IL-4 and IL-13 pathway inhibition, IL-13 targeting, and JAK pathway modulation have expanded treatment options beyond conventional topical anti-inflammatory therapy and emollient-based barrier repair. These advances reflect the growing understanding that eczema involves immune dysregulation, skin-barrier dysfunction, microbial imbalance, and neuroimmune itch pathways.

Commercial success now depends on evidence across severity bands, age groups, skin of color, comorbid asthma or allergic disease, and long-term safety. Payers are tightening step-therapy and prior-authorization requirements, while clinicians prioritize therapies that balance rapid itch relief, lesion clearance, adherence, safety monitoring burden, and sustained disease control in real-world practice.

Cumulative Impact of Artificial Intelligence in Eczema Therapeutics

Artificial intelligence is becoming a practical enabler in eczema therapeutics rather than a standalone therapy. AI-assisted imaging can help standardize lesion severity scoring, while machine learning can connect electronic health records, biomarkers, claims, prescription patterns, and patient-reported outcomes to identify treatment responders, flare risk, and adherence barriers.

In research and commercialization, AI supports trial-site selection, diverse patient recruitment, real-world evidence generation, adverse-event signal detection, medical content workflows, and digital patient support. Industry leaders must pair AI adoption with dermatology validation, bias testing across skin tones, privacy controls, explainable outputs, and transparent clinical governance to preserve trust and regulatory credibility.

Key Regional Insights: Asia-Pacific, Europe, North America, Latin America, Africa, and Middle East

Asia-Pacific is a high-priority eczema therapeutics region due to large pediatric populations, urbanization, pollution exposure, humid and variable climates, and expanding dermatology care in China, India, Japan, South Korea, and Australia. The region shows broad demand for affordable topical therapy, better diagnosis, and selective adoption of advanced immunology treatments where reimbursement and specialist infrastructure support use. North America remains a leading innovation and early-adoption environment, supported by FDA approvals, specialty pharmacy infrastructure, robust clinical-trial activity, and strong utilization of biologics and JAK inhibitors for moderate-to-severe atopic dermatitis.

Europe advances through centralized regulatory review, national health technology assessment discipline, pharmacovigilance rigor, and reimbursement evidence that shapes access after approval. Latin America shows increasing demand for eczema diagnosis and treatment, particularly in urban systems, but affordability, public-sector coverage, and specialist availability continue to influence uptake. The Middle East, led by Gulf health systems, is investing in specialty dermatology, private care, and advanced immunology access, while Africa remains comparatively underdiagnosed and underserved, making clinical education, essential topical anti-inflammatory therapy, emollient availability, infection control, and referral pathways central access priorities.

Key Group Insights Across NATO, G7, BRICS, European Union, ASEAN, and GCC

ASEAN markets are improving dermatology capacity, regulatory cooperation, and access to essential medicines, creating opportunities for affordable topical therapies, patient education, and selective biologic launches in higher-capacity urban systems. The GCC benefits from centralized procurement, private-sector specialty clinics, national health transformation programs, and high capacity for premium immunology brands, although formulary inclusion depends on clinical evidence, budget impact, and real-world value.

The European Union emphasizes centralized regulatory standards, pharmacovigilance, pediatric investigation planning, biosimilar readiness, and country-level reimbursement negotiations that determine practical access. BRICS countries combine large patient populations with price sensitivity, domestic manufacturing priorities, and uneven specialty access, making affordability and evidence localization essential. G7 markets set influential clinical, regulatory, safety, and reimbursement benchmarks for novel eczema therapeutics, while NATO countries increasingly treat medicine supply resilience, cybersecurity, cold-chain reliability, and manufacturing continuity as strategic healthcare concerns affecting specialty dermatology treatment access.

Key Country Insights for Eczema Therapeutics

The United States leads in specialty biologic and JAK inhibitor adoption, supported by clinical-trial density, guideline integration, and specialty pharmacy capabilities, while Canada balances access through public and private reimbursement review. Mexico and Brazil show rising demand for eczema therapeutics as urban diagnosis improves, but affordability, public-sector coverage, and uneven dermatologist access remain important constraints. The United Kingdom, Germany, France, Italy, and Spain are shaped by national health technology assessment, guideline adoption, budget impact review, and evidence requirements for long-term value, while Russia faces variability linked to supply, reimbursement, and access pathways.

China is expanding regulatory approvals, clinical research activity, and domestic innovation in dermatology, while India has major volume potential led by topical corticosteroids, emollients, antihistamine use for itch support, and improving specialty care in metropolitan centers. Japan, Australia, and South Korea demonstrate high regulatory quality, strong clinician awareness, and structured reimbursement pathways, making them important Asia-Pacific launch and evidence-generation markets. France, Germany, Italy, Spain, and the United Kingdom also remain central to European evidence development because their reimbursement decisions frequently influence broader access expectations across the region.

Actionable Recommendations for Eczema Therapeutics Leaders

Industry leaders should prioritize differentiated clinical evidence that demonstrates rapid itch reduction, skin clearance, quality-of-life improvement, durability, reduced steroid dependence, and safety in long-term maintenance therapy. Trial designs should include pediatric cohorts, adolescents, older adults, diverse skin tones, and real-world populations with asthma, allergic rhinitis, food allergy, sleep disturbance, mental health burden, and recurrent skin infection.

Commercial teams should build payer-ready value dossiers, adherence support, digital flare monitoring, patient education, and treatment-navigation resources for primary care, pediatrics, allergy, and dermatology networks. Organizations should also prepare lifecycle strategies around new formulations, label expansions, head-to-head evidence, real-world safety monitoring, companion digital tools, supply resilience, and market-specific pricing that reflects reimbursement capacity and access barriers.

Research Methodology

This executive summary is based on a structured secondary-research approach using regulatory labels and approval databases, dermatology and allergy guidelines, peer-reviewed epidemiology, clinical trial registries, health technology assessment outputs, disease-burden publications, reimbursement documents, and publicly available pharmacovigilance information.

Insights were triangulated across disease burden, treatment class, mechanism of action, reimbursement environment, regional access, patient outcomes, and competitive positioning. Emphasis was placed on verified clinical and commercial signals, including approved biologics, JAK inhibitors, topical anti-inflammatory therapies, guideline-recognized endpoints, safety communications, and real-world access dynamics, while avoiding market sizing, market share, and forecasting claims.

Conclusion: The Future of Eczema Therapeutics

Eczema therapeutics are entering a more evidence-intensive growth phase, led by targeted immunology, improved topical innovation, digital support tools, and greater attention to patient-reported itch, sleep, and quality of life. The treatment landscape is no longer defined only by corticosteroid use but by sequencing across chronic, relapsing disease, with therapy selection increasingly guided by severity, age, comorbidities, prior response, safety profile, and access conditions.

Winning organizations will combine clinical differentiation, safety transparency, payer evidence, inclusive research, and access strategies tailored to regional realities. As AI, real-world evidence, biomarker research, and precision dermatology mature, eczema therapeutics are positioned for continued innovation and broader patient impact across pediatric, adult, and underserved populations.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Eczema Therapeutics Market, by Therapeutic Class
7.1. Introduction
7.2. Corticosteroids
7.3. Calcineurin Inhibitors
7.4. PDE4 Inhibitors
7.5. Topical JAK Inhibitors
7.6. Oral JAK Inhibitors
7.7. Biologics
7.8. Conventional Systemic Immunosuppressants
7.9. Antihistamines
7.10. Anti-Infectives
8. Eczema Therapeutics Market, by Disease Indication
8.1. Introduction
8.2. Atopic Dermatitis
8.3. Contact Dermatitis
8.4. Dyshidrotic Eczema
8.5. Nummular Eczema
8.6. Seborrheic Dermatitis
8.7. Stasis Dermatitis
8.8. Neurodermatitis
9. Eczema Therapeutics Market, by Treatment Modality
9.1. Introduction
9.2. Topical Pharmacologic Therapy
9.3. Oral Systemic Therapy
9.4. Injectable Biologic Therapy
9.5. Device-Based Therapy
9.6. Maintenance Therapy
9.7. Adjunctive Non-Drug Therapy
10. Eczema Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Topical
10.2.1. Creams
10.2.2. Ointments
10.2.3. Lotions
10.2.4. Gels
10.2.5. Foams
10.2.6. Solutions
10.2.7. Sprays
10.3. Injectable
10.3.1. Subcutaneous
10.3.2. Intravenous
10.3.3. Intramuscular
10.4. Light-Based
10.4.1. Cabin-Based UVB
10.4.2. Hand-Foot UVB
10.4.3. Targeted Excimer
10.4.4. UVA-Based Systems
10.5. Dermal Support
10.5.1. Bath Additives
10.5.2. Medicated Cleansers
10.5.3. Impregnated Dressings
11. Eczema Therapeutics Market, by End User
11.1. Introduction
11.2. Dermatology Clinics
11.3. Physician Offices
11.4. Hospitals
11.5. Homecare Settings
12. Eczema Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Retail Pharmacies
12.4. Specialty Pharmacies
12.5. Online Pharmacies
12.6. Clinic-Based Channels
13. Eczema Therapeutics Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Eczema Therapeutics Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Eczema Therapeutics Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Acrotech Biopharma Inc.
17.3. Alliance Pharma plc
17.4. Almirall, S.A.
17.5. Amneal Pharmaceuticals, Inc.
17.6. Arcutis Biotherapeutics, Inc.
17.7. Astellas Pharma Inc.
17.8. Bausch Health Companies Inc.
17.9. Beiersdorf Aktiengesellschaft
17.10. Chugai Pharmaceutical Co., Ltd.
17.11. Cipla Limited
17.12. Dr. Reddy's Laboratories Limited
17.13. Ego Pharmaceuticals Pty Ltd
17.14. Eli Lilly and Company
17.15. Galderma Group AG
17.16. Glenmark Pharmaceuticals Limited
17.17. Hikma Pharmaceuticals PLC
17.18. Incyte Corporation
17.19. Japan Tobacco Inc.
17.20. Karo Healthcare AB
17.21. LEO Pharma A/S
17.22. Lupin Limited
17.23. Maruho Co., Ltd.
17.24. Organon & Co.
17.25. Otsuka Pharmaceutical Co., Ltd.
17.26. Padagis LLC
17.27. Perrigo Company plc
17.28. Pfizer Inc.
17.29. Pharmaceutical Specialties, Inc.
17.30. Pierre Fabre S.A.
17.31. Regeneron Pharmaceuticals, Inc.
17.32. Sandoz Group AG
17.33. Sanofi
17.34. Shionogi & Co., Ltd.
17.35. Sun Pharmaceutical Industries Limited
17.36. Teva Pharmaceutical Industries Ltd.
17.37. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL ECZEMA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ECZEMA THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ECZEMA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ECZEMA THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ECZEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ECZEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ECZEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TOPICAL JAK INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TOPICAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TOPICAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ORAL JAK INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ORAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ORAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CONVENTIONAL SYSTEMIC IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CONVENTIONAL SYSTEMIC IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CONVENTIONAL SYSTEMIC IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIHISTAMINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIHISTAMINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIHISTAMINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CONTACT DERMATITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CONTACT DERMATITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CONTACT DERMATITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL DYSHIDROTIC ECZEMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL DYSHIDROTIC ECZEMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL DYSHIDROTIC ECZEMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NUMMULAR ECZEMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NUMMULAR ECZEMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NUMMULAR ECZEMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SEBORRHEIC DERMATITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SEBORRHEIC DERMATITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SEBORRHEIC DERMATITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL STASIS DERMATITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL STASIS DERMATITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL STASIS DERMATITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NEURODERMATITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL NEURODERMATITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL NEURODERMATITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TOPICAL PHARMACOLOGIC THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TOPICAL PHARMACOLOGIC THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TOPICAL PHARMACOLOGIC THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ORAL SYSTEMIC THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL SYSTEMIC THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL SYSTEMIC THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL INJECTABLE BIOLOGIC THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INJECTABLE BIOLOGIC THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL INJECTABLE BIOLOGIC THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL DEVICE-BASED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL DEVICE-BASED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL DEVICE-BASED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ADJUNCTIVE NON-DRUG THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ADJUNCTIVE NON-DRUG THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ADJUNCTIVE NON-DRUG THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL LOTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LOTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LOTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL FOAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL FOAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL FOAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL SOLUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL SOLUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL SPRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL SPRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SPRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL LIGHT-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL LIGHT-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL LIGHT-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL CABIN-BASED UVB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CABIN-BASED UVB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CABIN-BASED UVB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL HAND-FOOT UVB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HAND-FOOT UVB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HAND-FOOT UVB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL TARGETED EXCIMER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL TARGETED EXCIMER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL TARGETED EXCIMER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL UVA-BASED SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL UVA-BASED SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL UVA-BASED SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL DERMAL SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL DERMAL SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL DERMAL SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL BATH ADDITIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL BATH ADDITIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL BATH ADDITIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL MEDICATED CLEANSERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL MEDICATED CLEANSERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL MEDICATED CLEANSERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL IMPREGNATED DRESSINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL IMPREGNATED DRESSINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL IMPREGNATED DRESSINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL PHYSICIAN OFFICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL PHYSICIAN OFFICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL PHYSICIAN OFFICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL CLINIC-BASED CHANNELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL CLINIC-BASED CHANNELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL CLINIC-BASED CHANNELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 177. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 179. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 180. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 181. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 182. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 183. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 184. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 185. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 186. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. EUROPE ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 210. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 211. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 212. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 213. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 214. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 216. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 217. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 218. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 219. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 222. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 223. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 224. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 225. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 226. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 227. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 228. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 229. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 230. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. MIDDLE EAST ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 232. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 233. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 234. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 235. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 236. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 237. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 239. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 240. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 241. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 242. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. NATO ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 245. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 246. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 247. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 248. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 250. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 251. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 252. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 253. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. G7 ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 256. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 257. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 258. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 259. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 261. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 262. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 263. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 264. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. BRICS ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 278. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 279. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 280. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 281. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 283. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 284. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 285. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 286. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. ASEAN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 289. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 290. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 291. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 292. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 293. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 294. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 295. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 296. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 297. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. GCC ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 300. CHINA ECZEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 302. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 303. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 304. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 305. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 306. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 307. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 308. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 309. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 310. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 311. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 313. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 314. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 315. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 316. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 317. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 318. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 322. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 324. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 325. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 326. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 327. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 328. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 329. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 330. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 331. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 332. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 333. INDIA ECZEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 335. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 336. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 337. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 338. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 339. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 340. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 341. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 342. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 343. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 344. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 345. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 346. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 347. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 348. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 349. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 350. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 351. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 352. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 353. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 354. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 355. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 356. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 357. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 358. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 359. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 360. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 361. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 362. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY LIGHT-BASED, 2017-2032 (USD MILLION)
TABLE 363. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY DERMAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 364. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 365. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 366. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, 20

Companies Mentioned

  • AbbVie Inc.
  • Acrotech Biopharma Inc.
  • Alliance Pharma plc
  • Almirall, S.A.
  • Amneal Pharmaceuticals, Inc.
  • Arcutis Biotherapeutics, Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Beiersdorf Aktiengesellschaft
  • Chugai Pharmaceutical Co., Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Ego Pharmaceuticals Pty Ltd
  • Eli Lilly and Company
  • Galderma Group AG
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Incyte Corporation
  • Japan Tobacco Inc.
  • Karo Healthcare AB
  • LEO Pharma A/S
  • Lupin Limited
  • Maruho Co., Ltd.
  • Organon & Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Padagis LLC
  • Perrigo Company plc
  • Pfizer Inc.
  • Pharmaceutical Specialties, Inc.
  • Pierre Fabre S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz Group AG
  • Sanofi
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.81 Billion
Forecasted Market Value ( USD ) by 2032 $ 13.26 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned37

Related Topics

Related Reports

Eczema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Eczema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Atopic Dermatitis - Competitive Landscape, 2026 - Product Image

Atopic Dermatitis - Competitive Landscape, 2026

  • Report
  • 240 Pages
  • Global
From
Atopic Dermatitis - Pipeline Insight, 2026 - Product Image

Atopic Dermatitis - Pipeline Insight, 2026

  • Clinical Trials
  • 280 Pages
  • Global
From
Atopic Dermatitis Drugs Market - Global Forecast 2026-2032 - Product Image

Atopic Dermatitis Drugs Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Atopic Dermatitis Drugs - Global Strategic Business Report - Product Image

Atopic Dermatitis Drugs - Global Strategic Business Report

  • Report
  • 351 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.